Diabetes

Pharmacists can guide patients in verifying sources, identifying licensed pharmacies, and understanding compounded vs FDA-approved products.

A randomized trial found that medically tailored groceries cut hemoglobin A1C by 0.40 points and sharply improved food security in adults with type 2 diabetes.

Preclinical data show a GLP-1 receptor agonist reprogrammed lung macrophages and prevented post-COVID pulmonary fibrosis in diabetic mice.

A global trial found the long-acting analogue reduced severe hypoglycemia and nighttime lows in youth with type 1 diabetes by 12 months, not 6.

Pharmacist-driven discharge medication reconciliation services identifies clinical interventions and may contribute to a decreased 30-day readmission rate.

New real-world data suggest pharmacists may have an expanding role in prioritizing GLP-1 therapy for patients managing both conditions.

Study authors suggest diabetic guidelines should consider standardized reporting of CGM metrics in studies employing CGM-based interventions.

Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP, shares the history and mission of NEIAP and explains how the organization provides practical education and networking opportunities.

In addition to explaining how NEIAP has evolved over time, Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, previews key topics at the upcoming September meeting.

Findings from a multicenter cohort study suggest glucagon-like peptide-1 (GLP-1) receptor agonist therapy may be associated with an elevated risk of sensory disturbances.

Phase 3 REIMAGINE data presented at ADA 2026 show the amylin–GLP-1 combination bests semaglutide monotherapy across type 2 diabetes stages, with implications for pharmacist-managed diabetes care.

The integrated CGM is now indicated for individuals 2 years and older who do not use insulin.

Approval of teplizumab-mzwv in patients aged 8 to 17 years makes it the first disease-modifying therapy for children newly diagnosed with stage 3 type 1 diabetes.

From prior authorization barriers to population health gaps, Cheeley explains why adherence — not initiation — is where pharmacists can make their biggest impact.

Pharmacy Times interviews Tracey Taveira, Pharm.D., CDOE, CVDOE, on the key challenges she discovered in optimizing cardio-renal risk in diabetes that she presented in ADA 2026.

Pharmacy Times interviews Tracey Taveira, Pharm.D., CDOE, CVDOE, to discuss pharmacist impact, VA system insights and practical lessons in cardio-renal diabetes care that she discussed in her presentation at ADA 2026.

Pharmacy Times speaks with Joyce Lee, PharmD, APh, FCCP, BCPS, BCACP, CDCES, to breakdown the diabetes education gap that clinicians can't afford to ignore.

A landmark joint guideline on cardiovascular-kidney-metabolic syndrome offers clinicians a comprehensive, stage-based road map for screening, prevention, and treatment of an increasingly prevalent interconnected condition.

Disparities in education access and quality, income level, and race and ethnicity are SDoH that make a major impact on diabetes and its management in the US.

Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children, adolescent, and adult patients with diabetes.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Donald Langan, PharmD, MD, a Multiple Sclerosis and Clinical Neuroimmunology Fellow at Columbia University, presenting on the evolution of GLP-1 receptor agonists, discussed the future of GLP-1 therapies and the expansion of the pharmacist's role.

As Novo Nordisk transitions patients from Rybelsus to newer, higher-efficacy oral semaglutide formulations, pharmacists are on the front lines of counseling, dosing clarification, and adverse effect management.

Community pharmacists emerged as the critical clinical link in the modern patient care continuum

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists should approach continuous glucose monitoring (CGM) report review and explains why individualized patient education is key.

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, explains how pharmacists can better leverage underutilized continuous glucose monitoring (CGM) app features and address the education gaps that prevent patients from achieving long-term CGM persistence.